組換えタンパク質の世界市場の評価：製品別、宿主細胞別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

世界の組換えタンパク質の市場規模は、2023年に25億1,000万米ドル、2031年に64億7,000万米ドルに達し、2024年～2031年の予測期間にCAGRで12.57%の成長が予測されています。市場は、診断と探索的研究の分野で著しい成長を記録しています。近年失効する生物製剤特許数の増加が、市場の需要を牽引しています。2022年～2027年に約31の生物製剤が独占権を失い、市場に巨大な需要を生み出すと予測されます。

バイオテクノロジーの分野における研究開発費の増加は、世界の組換えタンパク質市場の大幅な成長を促進しています。医療、研究、バイオテクノロジーの領域における組換えタンパク質の利用の拡大により、組換えタンパク質製品に対する需要は予測期間に増加すると予測されます。さらに、がん、自己免疫疾患、糖尿病などの慢性疾患の有病率の増加は、治療に生物製剤を必要とし、生物製剤市場の約60％に寄与しており、組換えタンパク質市場へより多くの企業を引き込むと予測されます。しかし、組換えタンパク質製造の特殊な要件と製品の高いコストは、市場の抑制要因です。

生物製剤の特許切れ件数の増加

生物製剤の特許切れ件数の増加が組換えタンパク質市場の成長を促進しています。生物製剤は生きた細胞から作られる複雑な分子であり、がん、自己免疫疾患、慢性腎臓病などのさまざまな疾患の治療に使用されます。複数の大ヒット生物製剤の特許がすでに切れているか切れる予定であるため、バイオシミラーやバイオ後続品の開発が進んでいます。これらの特許の失効は、バイオシミラーやバイオ後続品の開発機会を生み出し、市場の成長を促進しています。

研究開発投資の増加

研究開発への支出の増加は、組換えタンパク質市場に大きな影響を与えています。投資の増加は、革新的なプロテオミクス技術やゲノム技術の開発を促進し、組換えタンパク質の生産を促進しています。研究開発活動の高まりは特にアジア太平洋で顕著であり、市場参入企業に潜在的な成長機会を提供すると予測されています。研究開発費の急増は、市場拡大の重要な促進要因です。

サイトカイン・成長因子が予測期間に優位を占めると予測される

サイトカイン・成長因子セグメントは、がん、COVID-19、細胞培養、感染症、創傷治癒の研究における大きな役割のために優位に立つと予測されます。慢性疾患の有病率が増加し、治療に対する要求が高まっていることから、組換えタンパク質製品に対する需要が増加しています。これらの因子に関する研究開発は、サイトカイン・成長因子セグメントの優位性を推進しています。

北米が組換えタンパク質市場をリードする見込み

北米が世界の組換えタンパク質市場を独占しています。2022年、北米は収益シェアの大半を占め、今後もその地位を維持すると予測されます。同地域の優位性は、製薬産業における研究開発に向けた政府の資金提供戦略の利用可能性や、研究開発プログラムの増加、政府からの有利な資金調達に起因しています。北米市場で最大のシェアを占めるのは米国です。企業の競合の激化とエンドユーザーによるさまざまな利用が、製品パイプラインの拡大、新技術の開発、バイオプロセシングツールの進歩に寄与しています。

将来の市場シナリオ

世界の組換えタンパク質市場の見通しは有望であり、今後数年間に大きな成長が見込まれます。市場の促進要因は、慢性疾患の有病率の上昇、研究や学術部門におけるライフサイエンス技術の採用の拡大、主要な製薬企業やバイオテクノロジー企業の巨大なプレゼンスなどです。アジア太平洋は、研究活動の活発化、新製品開発、エンドユーザーによる利用の拡大により、大きな成長が見込まれています。市場は、サイトカイン、成長因子、抗体、免疫チェックポイントタンパク質などの製品によって独占されると予測されます。市場の主要企業は、Thermo Fisher Scientific, Inc.（米国）、R&D Systems（米国）、Abcam plc（英国）、Merck KGaA（ドイツ）などです。医療以外では、組換えタンパク質は農業、食品生産、バイオエンジニアリングで使用されており、近い将来さらに需要が増加すると予測されています。

当レポートでは、世界の組換えタンパク質市場について調査分析し、市場規模と予測、市場力学、主要企業情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の組換えタンパク質市場の見通し（2017年～2031年）

• 市場規模と予測
  • 金額
  • 数量
• 製品別
  • サイトカイン・成長因子
  • 抗体
  • 免疫チェックポイントタンパク質
  • ウイルス抗原
  • 酵素
  • 組換え調節タンパク質
  • ホルモン
  • その他
• 宿主細胞別
  • 哺乳類系
  • 昆虫細胞
  • 酵母・菌類
  • 細菌細胞
  • その他
• 用途別
  • 創薬・開発
  • 学術研究
  • バイオ医薬品生産
  • バイオテクノロジー研究
  • 診断
  • その他の用途
• エンドユーザー別
  • 製薬企業、バイオテクノロジー企業
  • 学術・研究機関
  • 臨床研究組織
  • 診断研究所
  • その他
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
• 市場シェア：企業別（2023年）

第5章 世界の組換えタンパク質市場の見通し：地域別（2017年～2031年）

• 北米
  • 市場規模と予測
  • 製品別
  • 宿主細胞別
  • 用途別
  • エンドユーザー別
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド
• 南米
  • ブラジル
  • アルゼンチン
• アジア太平洋
  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第6章 市場マッピング（2023年）

• 製品別
• 宿主細胞別
• 用途別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入の分析 - 数量と金額
• サプライ/バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長抑制要因（課題、抑制要因）

第9章 規制枠組みとイノベーション

• 臨床試験
• 特許情勢
• 規制当局の承認
• イノベーション/新技術

第10章 主要企業情勢

• マーケットリーダー上位5社の競合マトリクス
• マーケットリーダー上位5社の市場収益分析（2023年）
• 合併と買収/合弁事業（該当する場合）
• SWOT分析（市場参入企業5社）
• 特許分析（該当する場合）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Abbvie Inc.
• Amgen Inc.
• Bio-Rad Laboratories Inc.
• Eli Lilly and Company
• Merck KGaA
• Novo Nordisk AS
• Sanofi SA
• Thermo Fisher Scientific Inc.
• Novartis AG
• GlaxoSmithKline PLC
• Novavax Inc.
• Pfizer Inc.

第14章 戦略的推奨事項

第15章 当社について、免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 3. Global Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 4. Global Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 5. Global Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 6. Global Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 7. Global Recombinant Proteins Market Share (%), By Region, 2017-2031F
• Figure 8. North America Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 9. North America Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 10. North America Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 11. North America Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 12. North America Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 13. North America Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 14. North America Recombinant Proteins Market Share (%), By Country, 2017-2031F
• Figure 15. United States Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 16. United States Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 17. United States Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 18. United States Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 19. United States Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 20. United States Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 21. Canada Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 22. Canada Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 23. Canada Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 24. Canada Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 25. Canada Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 26. Canada Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 27. Mexico Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 28. Mexico Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 29. Mexico Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 30. Mexico Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 31. Mexico Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 32. Mexico Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 33. Europe Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 34. Europe Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 35. Europe Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 36. Europe Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 37. Europe Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 38. Europe Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 39. Europe Recombinant Proteins Market Share (%), By Country, 2017-2031F
• Figure 40. Germany Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 41. Germany Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 42. Germany Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 43. Germany Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 44. Germany Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 45. Germany Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 46. France Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 47. France Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 48. France Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 49. France Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 50. France Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 51. France Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 52. Italy Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Italy Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 54. Italy Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 55. Italy Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 56. Italy Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 57. Italy Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 58. United Kingdom Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 59. United Kingdom Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 60. United Kingdom Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 61. United Kingdom Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 62. United Kingdom Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 63. United Kingdom Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 64. Russia Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Russia Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 66. Russia Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 67. Russia Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 68. Russia Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 69. Russia Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 70. Netherlands Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 71. Netherlands Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 72. Netherlands Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 73. Netherlands Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 74. Netherlands Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 75. Netherlands Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 76. Spain Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 77. Spain Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 78. Spain Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 79. Spain Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 80. Spain Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 81. Spain Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 82. Turkey Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 83. Turkey Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 84. Turkey Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 85. Turkey Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 86. Turkey Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 87. Turkey Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 88. Poland Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 89. Poland Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 90. Poland Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 91. Poland Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 92. Poland Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 93. Poland Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 94. South America Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 95. South America Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 96. South America Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 97. South America Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 98. South America Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 99. South America Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 100. South America Recombinant Proteins Market Share (%), By Country, 2017-2031F
• Figure 101. Brazil Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 102. Brazil Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 103. Brazil Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 104. Brazil Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 105. Brazil Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 106. Brazil Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 107. Argentina Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 108. Argentina Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 109. Argentina Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 110. Argentina Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 111. Argentina Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 112. Argentina Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 113. Asia-Pacific Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 114. Asia-Pacific Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 115. Asia-Pacific Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 116. Asia-Pacific Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 117. Asia-Pacific Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 118. Asia-Pacific Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 119. Asia-Pacific Recombinant Proteins Market Share (%), By Country, 2017-2031F
• Figure 120. India Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 121. India Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 122. India Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 123. India Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 124. India Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 125. India Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 126. China Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 127. China Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 128. China Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 129. China Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 130. China Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 131. China Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 132. Japan Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 133. Japan Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 134. Japan Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 135. Japan Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 136. Japan Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 137. Japan Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 138. Australia Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 139. Australia Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 140. Australia Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 141. Australia Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 142. Australia Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 143. Australia Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 144. Vietnam Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 145. Vietnam Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 146. Vietnam Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 147. Vietnam Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 148. Vietnam Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 149. Vietnam Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 150. South Korea Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 151. South Korea Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 152. South Korea Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 153. South Korea Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 154. South Korea Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 155. South Korea Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 156. Indonesia Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 157. Indonesia Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 158. Indonesia Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 159. Indonesia Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 160. Indonesia Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 161. Indonesia Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 162. Philippines Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 163. Philippines Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 164. Philippines Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 165. Philippines Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 166. Philippines Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 167. Philippines Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 168. Middle East & Africa Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 169. Middle East & Africa Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 170. Middle East & Africa Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 171. Middle East & Africa Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 172. Middle East & Africa Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 173. Middle East & Africa Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 174. Middle East & Africa Recombinant Proteins Market Share (%), By Country, 2017-2031F
• Figure 175. Saudi Arabia Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 176. Saudi Arabia Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 177. Saudi Arabia Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 178. Saudi Arabia Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 179. Saudi Arabia Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 180. Saudi Arabia Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 181. UAE Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 182. UAE Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 183. UAE Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 184. UAE Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 185. UAE Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 186. UAE Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 187. South Africa Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
• Figure 188. South Africa Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
• Figure 189. South Africa Recombinant Proteins Market Share (%), By Product, 2017-2031F
• Figure 190. South Africa Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
• Figure 191. South Africa Recombinant Proteins Market Share (%), By Application, 2017-2031F
• Figure 192. South Africa Recombinant Proteins Market Share (%), By End-user, 2017-2031F
• Figure 193. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194. By Host Cell Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global Recombinant Proteins market size was valued at USD 2.51 billion in 2023, and is expected to reach USD 6.47 billion in 2031, with a CAGR of 12.57% for the forecast period between 2024 and 2031F. The recombinant protein market has registered significant growth in the field of diagnostic and exploratory research. The increase in the number of biologics patents expiring recently is driving demand for the recombinant protein market. About 31 biologics will lose exclusivity between 2022 and 2027 which is expected to create huge demand in the market.

Increasing expenditure on research and development in the field of biotechnology is promoting significant growth in the global recombinant proteins market. Due to the expansion of applications of recombinant proteins in the domain of medicine, research, and biotechnology, the demand for recombinant protein products is expected to increase during the forecast period. Additionally, the growing prevalence of chronic diseases like cancer, auto-immune diseases, and diabetes require biologics for treatment and contribute to about 60% of the biologics market, which is expected to draw more business in the recombinant proteins market. However, specific requirements of recombinant protein production and high cost of products are some of the factors restraining recombinant proteins market.

For instance, in June 2022, Navigo Proteins GmbH, a leading provider of affinity ligands for customized chromatography solutions and protein engineering, developed an affinity resin to capture the glycoprotein gp64, an unwanted contaminant from the baculovirus insect cell production system. By effectively utilizing precision capturing technology, Navigo was able to create a Precision X ligand that binds to the gp64 contaminant.

Increase in Number of Biologics Patent Expiration

The increasing number of biologics patent expiry is driving the growth of the recombinant proteins market. Biologics are complex molecules produced from living cells and are used to treat various diseases such as cancer, autoimmune diseases, and chronic kidney disease. Patents for several blockbuster biologics have expired or are set to expire, leading to the development of biosimilars and follow-on biologics. The expiration of these patents has created opportunities for the development of biosimilars and follow-on biologics, which are driving the growth of the recombinant proteins market.

According to The Center for Biosimilar, by 2023, patents on nearly 20 oncology biologics will expire. The highest-earning drug, Humira is losing exclusivity in the year 2023, opening a huge opportunity for the biosimilar market. Johnson & Johnson's Stelara is going off-patent in the second half of 2023 which is a promising candidate for the biosimilar market.

Increasing Investment in Research and Development

The increasing expenditure on research and development is significantly impacting the recombinant proteins market. The heightened investment is driving the development of innovative proteomic and genomic techniques, thereby fostering the production of recombinant proteins. The growing R&D initiatives are particularly notable in Asia-Pacific, which is expected to offer potential growth opportunities for market players. The surge in research and development spending is a key driver propelling the expansion of the recombinant proteins market. In February 2023, in a seed extension round, Canadian startup Future Fields secured USD 11.2 million to expand the use of fruit flies as high-value recombinant protein production machines. The firm aims to produce recombinant proteins at a large scale in 10,000 square feet of manufacturing space.

Cytokines and Growth Factors are Expected to Dominate During Forecast Period

The cytokines and growth factors segment is expected to dominate due to its vast role in research in cancer, COVID-19, cell culture, infectious diseases, and wound healing. The increasing prevalence of chronic diseases and their growing treatment requirements has led to an increase in demand for recombinant protein products. Research and development around these factors are propelling the dominance of cytokines and growth factors segment. In September 2023, Sino Biological, Inc. launched several products for biological research including four high-quality recombinant cytokines and GMP grade cytokines.

North America is Expected to be Lead the Recombinant Proteins Market

North America dominates the global recombinant proteins market. In 2022, North America accounted for a significant portion of the revenue share, and it is expected to maintain its position in the coming years. The region's dominance can be attributed to the availability of funding government initiatives for R&D in the pharmaceutical industry, more R&D programs, and a favorable funding from the government. The United States accounted for the largest share in the North America recombinant proteins market. The growth in competition among players and diverse applications by end-users has contributed to the expansion of product pipelines, the development of new technologies, and the advancement of bioprocessing tools.

Future Market Scenario

The outlook for the global recombinant proteins market appears to be promising, with significant growth expected in the coming years. The market is driven by factors such as the rising prevalence of chronic diseases, the growing adoption of life science techniques in research and academia, and the huge presence of major pharmaceutical and biotechnology companies. Asia-Pacific is projected to witness significant growth due to increasing research activities, new product development, and expanding applications by end-users. The market for recombinant proteins is expected to be dominated by products such as cytokines, growth factors, antibodies, and immune checkpoint proteins. Key players in the recombinant proteins market include Thermo Fisher Scientific, Inc. (US), R&D Systems (US), Abcam plc (UK), Merck KGaA (Germany), and others. Apart from healthcare, recombinant proteins are used in agriculture, food production, and bioengineering, which is further expected to increase demand in the near future.

Key Players Landscape and Outlook

Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using a variety of strategies. To gain market share, companies are expanding the range of products they offer. Industry participants use a variety of growth methods, including collaborations, mergers and acquisitions, product launches, and the development of new goods, to bolster their position in the market.

In January 2022, Thermo Fisher Scientific Inc. completed the acquisition of PeproTech, Inc. for a total cash purchase price of approximately USD 1.85 billion. PeproTech was a leading manufacturer of recombinant proteins in the United States. The acquisition strengthened the recombinant portfolio of Thermo Fisher Scientific.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Recombinant Proteins Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Product
  • 4.2.1. Cytokines and Growth Factors
    • 4.2.1.1. Interferons (IFNs)
    • 4.2.1.2. Interleukins (ILs)
    • 4.2.1.3. Others
  • 4.2.2. Antibodies
  • 4.2.3. Immune Checkpoint Proteins
  • 4.2.4. Virus Antigens
  • 4.2.5. Enzymes
    • 4.2.5.1. Kinases
    • 4.2.5.2. Metabolic enzymes
    • 4.2.5.3. Others
  • 4.2.6. Recombinant Regulatory Protein
  • 4.2.7. Hormones
  • 4.2.8. Others
• 4.3. By Host Cell
  • 4.3.1. Mammalian Systems
  • 4.3.2. Insect Cells
  • 4.3.3. Yeast and Fungi
  • 4.3.4. Bacterial Cells
  • 4.3.5. Others
• 4.4. By Application
  • 4.4.1. Drug Discovery and Development
    • 4.4.1.1. Biologics
    • 4.4.1.2. Vaccines
    • 4.4.1.3. Cell and Gene Therapy
  • 4.4.2. Academic Research Studies
  • 4.4.3. Biopharmaceutical Production
  • 4.4.4. Biotechnology Research
  • 4.4.5. Diagnostics
  • 4.4.6. Other Applications
• 4.5. By End-user
  • 4.5.1. Pharmaceutical and Biotechnology Companies
  • 4.5.2. Academics and Research Institutions
  • 4.5.3. Clinical Research Organization
  • 4.5.4. Diagnostic Laboratories
  • 4.5.5. Others
• 4.6. By Region
  • 4.6.1. North America
  • 4.6.2. Europe
  • 4.6.3. Asia Pacific
  • 4.6.4. South America
  • 4.6.5. Middle East & Africa
• 4.7. By Company Market Share (%), 2023

5. Global Recombinant Proteins Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
    • 5.1.1.2. By Volume
  • 5.1.2. By Product
    • 5.1.2.1. Cytokines and Growth Factors
    • 5.1.2.1.1. Interferons (IFNs)
    • 5.1.2.1.2. Interleukins (ILs)
    • 5.1.2.1.3. Others
    • 5.1.2.2. Antibodies
    • 5.1.2.3. Immune Checkpoint Proteins
    • 5.1.2.4. Virus Antigens
    • 5.1.2.5. Enzymes
    • 5.1.2.5.1. Kinases
    • 5.1.2.5.2. Metabolic enzymes
    • 5.1.2.5.3. Others
    • 5.1.2.6. Recombinant Regulatory Protein
    • 5.1.2.7. Hormones
    • 5.1.2.8. Others
  • 5.1.3. By Host Cell
    • 5.1.3.1. Mammalian Systems
    • 5.1.3.2. Insect Cells
    • 5.1.3.3. Yeast and Fungi
    • 5.1.3.4. Bacterial Cells
    • 5.1.3.5. Others
  • 5.1.4. By Application
    • 5.1.4.1. Drug Discovery and Development
    • 5.1.4.1.1. Biologics
    • 5.1.4.1.2. Vaccines
    • 5.1.4.1.3. Cell and Gene Therapy
    • 5.1.4.2. Academic Research Studies
    • 5.1.4.3. Biopharmaceutical Production
    • 5.1.4.4. Biotechnology Research
    • 5.1.4.5. Diagnostics
    • 5.1.4.6. Other Applications
  • 5.1.5. By End-user
    • 5.1.5.1. Pharmaceutical and Biotechnology Companies
    • 5.1.5.2. Academics and Research Institutions
    • 5.1.5.3. Clinical Research Organization
    • 5.1.5.4. Diagnostic Laboratories
    • 5.1.5.5. Others
  • 5.1.6. United States*
    • 5.1.6.1. Market Size & Forecast
    • 5.1.6.1.1. By Value
    • 5.1.6.1.2. By Volume
    • 5.1.6.2. By Product
    • 5.1.6.2.1. Cytokines and Growth Factors
    • 5.1.6.2.1.1. Interferons (IFNs)
    • 5.1.6.2.1.2. Interleukins (ILs)
    • 5.1.6.2.1.3. Others
    • 5.1.6.2.2. Antibodies
    • 5.1.6.2.3. Immune Checkpoint Proteins
    • 5.1.6.2.4. Virus Antigens
    • 5.1.6.2.5. Enzymes
    • 5.1.6.2.5.1. Kinases
    • 5.1.6.2.5.2. Metabolic enzymes
    • 5.1.6.2.5.3. Others
    • 5.1.6.2.6. Recombinant Regulatory Protein
    • 5.1.6.2.7. Hormones
    • 5.1.6.2.8. Others
    • 5.1.6.3. By Application
    • 5.1.6.3.1. Drug Discovery and Development
    • 5.1.6.3.1.1. Biologics
    • 5.1.6.3.1.2. Vaccines
    • 5.1.6.3.1.3. Cell and Gene Therapy
    • 5.1.6.3.2. Academic Research Studies
    • 5.1.6.3.3. Biopharmaceutical Production
    • 5.1.6.3.4. Biotechnology Research
    • 5.1.6.3.5. Diagnostics
    • 5.1.6.3.6. Other Applications
    • 5.1.6.4. By End-user
    • 5.1.6.4.1. Pharmaceutical and Biotechnology Companies
    • 5.1.6.4.2. Academics and Research Institutions
    • 5.1.6.4.3. Clinical Research Organization
    • 5.1.6.4.4. Diagnostic Laboratories
    • 5.1.6.4.5. Others
  • 5.1.7. Canada
  • 5.1.8. Mexico

All segments will be provided for all regions and countries covered:

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. South America
  • 5.3.1. Brazil
  • 5.3.2. Argentina
• 5.4. Asia-Pacific
  • 5.4.1. India
  • 5.4.2. China
  • 5.4.3. Japan
  • 5.4.4. Australia
  • 5.4.5. Vietnam
  • 5.4.6. South Korea
  • 5.4.7. Indonesia
  • 5.4.8. Philippines
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Product
• 6.2. By Host Cell
• 6.3. By Application
• 6.4. By End-user
• 6.5. By Region

7. Macro Environment and Industry Structure

• 7.1. Supply Demand Analysis
• 7.2. Import Export Analysis - Volume and Value
• 7.3. Supply/Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges, Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Abbvie Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Amgen Inc.
• 13.3. Bio-Rad Laboratories Inc.
• 13.4. Eli Lilly and Company
• 13.5. Merck KGaA
• 13.6. Novo Nordisk AS
• 13.7. Sanofi SA
• 13.8. Thermo Fisher Scientific Inc.
• 13.9. Novartis AG
• 13.10. GlaxoSmithKline PLC
• 13.11. Novavax Inc.
• 13.12. Pfizer Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer